Established in May, 2005, Weihai Disu Pharmaceutical Co., Ltd., a subsidiary of Disha Pharmaceutical Group, is a national high-tech enterprise majoring in R&D, manufacturing and marketing of APIs and intermediates.

Relying on the R&D strength of Disha Pharmaceutical Group, Weihai Disu Pharmaceutical Co., Ltd. has built an institute with 100 researchers. Besides that, four other research institutes in Disha Group will constantly provide Weihai Disu with technical supports of science research and process optimization.

Weihai Disu performs strictly to the standards of Ch.P, Eh.P, USP and JP. The API registrations in EU, Japan, Korea and India are also in process. Glipizide has been registered in EU.